HDAC9 and hepatocellular carcinoma: While unresolved HDACi-associated issues continue to persist, including but not limited to a broad spectrum of HDAC isoform inhibition, non-selective or genome-wide modulation of gene expressions, and side effects, the use of HDACi alone or combined with other anticancer drugs remains an attractive therapeutic option for HCC.